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Rett syndrome (RTT) is a neurodevelopmental disorder with no efficient treatment that is caused in the
majority of cases by mutations in the gene methyl-CpG binding-protein 2 (MECP2). RTT becomes manifest
after a period of apparently normal development and causes growth deceleration, severe psychomotor
impairment and mental retardation. Effective animal models for RTT are available and show morphofunc-
tional abnormalities of synaptic connectivity. However, the molecular consequences of MeCP2 disruption
leading to neuronal and synaptic alterations are not known. Protein synthesis regulation via the mammalian
target of the rapamycin (mTOR) pathway is crucial for synaptic organization, and its disruption is involved in
a number of neurodevelopmental diseases. We investigated the phosphorylation of the ribosomal protein (rp)
S6, whose activation is highly dependent from mTOR activity. Immunohistochemistry showed that rpS6
phosphorylation is severely affected in neurons across the cortical areas of Mecp2 mutants and that this
alteration precedes the severe symptomatic phase of the disease. Moreover, we found a severe defect of
the initiation of protein synthesis in the brain of presymptomatic Mecp2 mutant that was not restricted to
a specific subset of transcripts. Finally, we provide evidence for a general dysfunction of the Akt/mTOR,
but not extracellular-regulated kinase, signaling associated with the disease progression in mutant brains.
Our results indicate that defects in the AKT/mTOR pathway are responsible for the altered translational con-
trol in Mecp2 mutant neurons and disclosed a novel putative biomarker of the pathological process.
Importantly, this study provides a novel context of therapeutic interventions that can be designed to success-
fully restrain or ameliorate the development of RTT.
INTRODUCTION
Rett syndrome (RTT; MIM312750) is a pediatric neurological
progressive disorder leading to severe mental retardation,
psychomotor impairment and autistic behavior that affects
about 1:10 000 girls worldwide (1–3). Children with RTT
have apparently normal development until 6 months of life,
after which they undergo a rapid regression marked by a
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deceleration of head growth, the onset of stereotyped hand
movements, irregular breathing and seizures (4). Loss-of-
function mutations in the X-linked methyl-CpG-binding
protein 2 (MECP2) gene, a transcriptional regulator that acts
through epigenetic mechanisms on chromatin structure (5),
cause the 95% of RTT cases. Importantly, mutations of this
gene are also found in patients with other neurological con-
ditions such as Angelman-like syndrome, motor and learning
disabilities, seizures, bipolar disease, juvenile-onset schizo-
phrenia, neonatal encephalopathy and autism (2,6,7). The
finding that in mice targeted the mutation of Mecp2 in the
central nervous system may produce a phenotype similar to
the whole-body mutation has suggested that impairment of
MeCP2 function in the brain is crucial for the pathogenesis
of the disease (8,9). Indeed, the analysis of the available
animal models for RTT has indicated that altered MeCP2
levels in neurons cause morphological defects in both dendri-
tic complexity, spine number as well as alterations in synaptic
transmission and plasticity (10–16). These results have
suggested a model for the etiopathogenesis of RTT in which
the behavioral alterations induced by the Mecp2 mutation
could depend on the modifications of brain synaptic organiz-
ation. However, the molecular events leading from the disrup-
tion of Mecp2 expression in the brain to the alterations of
neuronal circuits are yet not known.
There is mounting evidence showing that aberrant neuronal
protein synthesis as one underlying cause of the clinical
features of autism spectrum disorders (17,18). Alterations of
signaling cascades involved in the regulation protein synthesis,
such as the mammalian target of rapamycin (mTOR) and
phosphoinositide 3-kinase (PI3K) pathways, have been
involved in neurodevelopmental diseases associated with
severe mental retardation (19,20) such as Fragile X (21),
tuberous sclerosis (22) and Phelan-McDermid syndrome
(23). Interestingly, the regulation of protein synthesis via the
mTOR/PI3K pathway is crucially involved in synaptic func-
tion, structure and plasticity (20,24–26). In post-mitotic
neurons, mTOR activity and its downstream targets can
control the size of the neuronal cell soma, axon pathfinding
and regeneration, dendrite arborization, dendritic spine
morphology and synaptic plasticity (20,25). Intriguingly, all
these aspects are altered in Mecp2 mutants. These changes
are not accompanied, surprisingly, by important changes in
the transcriptome (1,27,28), suggesting that Mecp2 may
subtly act at the post-transcriptional level. In spite of it,
studies describing the efficacy of protein synthesis or the
translation-related intracellular signaling in RTT are not yet
available.
In this study, we investigate whether the activation of
ribosomal protein (rp) S6, a component of the 40S ribosomal
subunit, is normal during the post-natal brain development of
Mecp2 mutant mice. In particular, we analyze the modifi-
cations occurring at Ser235/236 and Ser240/244. These
residues can be phosphorylated by both the extracellular-
regulated kinase (ERK) and the mTOR/PI3K pathway and
correlate with cellular translational rates (29–31). Moreover,
to test the hypothesis that translational deficits may be a
cause of RTT neurological dysfunctions, we looked at polyso-
mal complexity and polysome-associated mRNAs in the brain
of Mecp2 mutants. Finally, we analyze the contribution of
intracellular upstream signaling to dissect out the mechanism
regulating protein synthesis in neurons completely lacking
Mecp2.
RESULTS
Pervasive hypophosphorylation of rpS6 inMecp22/y brains
precedes symptoms manifestation
mTOR/PI3K-dependent protein synthesis in neurons is crucial
for the organization of neuronal and synapse structures (e.g.
dendrites and dendritic spines) as well as for synaptic plas-
ticity (24–26). In addition, dendritic protein synthesis
induced by activation and plasticity of synaptic connections
requires the action of ERK-dependent signaling (24,32,33).
To address weather possible defects of these intracellular path-
ways might occur in the brain of Mecp2 knock-out (KO) mice
(Mecp2tml.lJae) (8), we examined the immunolocalization of
phosphorylated (p) rpS6, a converging target of both ERK
and mTOR/PI3K activity (31). We analyzed the localization
of activated rpS6 in the primary sensory (S1) cortex and in
the CA1 region of the hippocampus, where neuronal and
synaptic alterations have previously been found in mice
models of RTT (10,12,15,34–37). The analysis was performed
in Mecp22/y mice at 8 weeks of age (P56) showing clear
symptomatic signs (i.e. locomotor impairments, hind limb
clasping, perseverative scratching and breathing irregulari-
ties). Sections were probed with two specific antibodies. The
first recognizes rpS6 only when is activated at Ser235/236,
two residues that can be phosphorylated by both ERK and
mTOR/PI3K activities. The second antibody recognizes the
activated form of rpS6 at Ser240/244 sites, a modification
that can be induced by the action of the mTOR/PI3K
pathway and is ERK-independent.
As illustrated in Figure 1A, we observed a robust decrease
in p-rpS6 immunoreactivity throughout the S1 cortex of
Mecp2 mutants compared with wild-type (WT) littermates.
In general, rpS6 activation was more intense in layer 5 of
the cortex of WT animals. A close inspection of the immuno-
labeled sections revealed that in individual cortical neurons,
rpS6 can be activated both in the soma and in the most prox-
imal portion of the apical dendrite. As can be inferred in
Figure 1A insets, rpS6 staining showed differences among
the cells. Remarkably, quantification of the immunosignal
intensity (Fig. 1D), calculated as optical density (OD) values
of the peroxidase staining, confirmed a significant decrease
in rpS6 activation at both Ser235/236 and Ser240/244 in the
Mecp2 mutants. We found a 32.2% reduction in p-rpS6
(Ser235/236) activation throughout the cortex of KO mice in
comparison with WT littermates (n ¼ 3, P , 0.005),
whereas the activation of p-rpS6 (Ser240/244) was 30.2%
less in the mutants than in control animals (n ¼ 3, P ,
0.05). In contrast, we detected neither differences in localiz-
ation (Fig. 1A) nor significant changes in immunolabeling
intensity (Fig. 1B) for the total rpS6 protein between WT
and Mecp22/y mice. Thus, because of reduced phosphoryl-
ation, rpS6 cannot properly function in symptomatic Mecp2
KO male mice.
To address whether dysfunctional rpS6 phosphorylation
in the cortex may either anticipate or correlate with the
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disease progression, we next examined KO animals at earlier
post-natal ages (i.e. P14 and P28). As illustrated in
Figure 1C, at P28, i.e. before the appearance of evident loco-
motor deficits and hind limb clasping in Mecp2 KO mice,
mutants show a significative reduction in p-rpS6 immuno-
reactive signals (p-rpS6-Ser235/236: 23.6% reduction in KO
mice versus WT littermates, n ¼ 3 WT and KO, P , 0.005;
p-rpS6-Ser240/244: 41.4% reduction in KO mice versus WT
littermates, n ¼ 3 WT and KO, P, 0.001). Intriguingly, at
an earlier post-natal developmental stage (P14), when
mutants are asymptomatic, KO mice showed WT levels of
rpS6 activation (Fig. 1B). At this early post-natal developmen-
tal stage, we detected no differences in rpS6 immunostaining
intensity for any of the phosphorylation sites throughout the
cortical layers. Quantitative evaluation of rpS6 immunostain-
ing showed no differences between the two genotypes at
Figure 1. The loss of MeCP2 leads to defective rpS6 activation in the S1 cortex of adult mice. (A) Representative micrographs of S1 cortex cryosections of
symptomatic mice at 56 days of age showing the reduction in both p-rpS6 (Ser235/236) and p-rpS6 (Ser240/244) immunoreactivity in MeCP2 KO animals.
Total rpS6 immunoreactivity is unchanged between WT and control animals. Insets show higher magnification views of the immunolabeling in layer V
neurons. Reduced cortical thickness shown by MeCP2 KO sections compared with WT controls is representative of a previously reported morphological altera-
tion affecting mutants (61) and is not due to fixation artifacts or a mismatch of cortical areas that were examined in this study. (B–D) Histograms illustrate the
evaluation of rpS6 phosphorylation levels as well as total rpS6 expression in each layer (I–VI) of the S1 cortex. Data are expressed as the mean OD values of the
immunoperoxidase labeling. (B) At P14, labeling intensity for both the activated and the total rpS6 shows no statistically significant variations between KO mice
and WT littermates. The decrease in p-rpS6 (Ser235/236 and Ser240/244) labeling intensity is highly significant and is spread throughout the cortical layers of
P28 (C) and P56 (D) KO mice compared with WT littermates. Total rpS6 expression is not altered in these animals. Data are expressed as the mean+ sem. ∗P,
0.05, ∗∗P , 0.01, ∗∗∗P , 0.001 (scale bar, 100 mm).
1184 Human Molecular Genetics, 2011, Vol. 20, No. 6
 at Universita degli Studi dell'Insubria on August 23, 2011
hm
g.oxfordjournals.org
Downloaded from
 
both P14 and P28 (Fig. 1C and D). These data indicate that
after a period of putative normal activity, rpS6 becomes hypo-
functional in correlation with the onset of the symptoms.
To determine whether rpS6 phosphorylation may be simi-
larly affected in other brain areas, we, next, performed a
similar immunohistochemical analysis of p-rpS6 localization
in the CA1 hippocampal area of Mecp2 mutants at the three
ages examined previously. Interestingly, although CA1 pyra-
midal neurons in MeCP2 KO mice showed less rpS6 acti-
vation than WT animals (Supplementary Material, Fig. S1)
the effect was less dramatic than what we observed in the
S1 cortex. In particular, we found that there is a significant
decrease in rpS6 activation on Ser240/244 in P28 KO mice
(Supplementary Material, Fig. S1D; OD WT: 0.16+ 0.02;
OD KO: 0.08+ 0.01; n ¼ 3 WT and KO, P , 0.05).
It has been recently shown that glial cells lacking MeCP2
may cause defects in the dendritic morphology and complexity
of co-coltured MeCP2-positive neurons thus implying a criti-
cal role of the glia in the neurological alterations associated
with RS (38). To explore whether the rpS6 phosphorylation
changes observed in Mecp2 (P28) mutants are associated
with alterations occurring also in glial cells we analyzed
rpS6 phosphorylation in dually labeled brain sections with
antibodies against GFAP or NeuN. As illustrated in Figure
S2, the number of GFAP+ glial cells was very low throughout
the layers of the S1 cortex in both WT and mutant animals.
Moreover, virtually no co-localization between GFAP+ cells
and p-rpS6-Ser235/236 or p-rpS6-Ser240/244 immunosignal
was detectable in sections from both genotypes (Supplemen-
tary Material, Fig. S2A and B) indicating that rpS6 shows
extremely low levels of activation in glial cells. In contrast,
we found that practically all p-rpS6+ cortical cells were
clearly co-labeled with NeuN antibody (Supplementary
Material, Fig. S2A and B). Importantly, the specific neuronal
rpS6 activation was also observed in labeled sections from
the CA1 area of the hippocampus (Supplementary Material,
Fig. S2A and B). Indeed, while p-rpS6 immunofluorescence
was not detectable in GFAP+ cells, NeuN+ CA1 pyramidal
neurons were co-labeled with the p-rpS6 antibodies. Thus,
these data suggest that the consequences of rpS6 hypofunction
in the brain of Mecp2 mutants are primarily attributable to
neuronal activation defects.
In a second approach, we independently quantify the
reduction in the rpS6 phosphorylation levels at Ser235/236
and Ser240/244 by western blot analysis carried out on three
isolated brain regions, i.e. cerebral cortex, hippocampus and
cerebellum. Phosphorylated rpS6 levels were confirmed to
be strongly decreased in cortex and cerebellum and, to a
lesser extent, in the hippocampus of brains lacking Mecp2,
whereas total rpS6 levels were unaltered (cortex:
p-rpS6-Ser235/236, reduced to 55.1+ 11.1% of WT levels,
n ¼ 9, P ¼ 0.001; p-rpS6-Ser240/244, reduced to 35.2+
10.7% of WT levels, N ¼ 8 P ¼ 0.009; cerebellum:
p-rpS6-Ser235/236, reduced to 31.9+ 6.5% of WT levels,
n ¼ 6, P ¼ 0.005; p-rpS6-Ser240/244, reduced to 29.5+
12.6% of WT levels, n ¼ 4, P ¼ 0.002; hippocampus:
p-rpS6-Ser235/236, reduced to 56.2+ 5.6% of WT levels,
n ¼ 4, P ¼ 0.02; p-rpS6-S240/244, reduced to 68.9+ 16.6%
of WT levels, n ¼ 11, P ¼ 0.15; Fig. 2A–C). In general, we
found a decrease in phosphorylation in Ser240/244 and
Ser235/236, except for the hippocampus, where the reduction
in Ser240/244 phosphorylation was not statistically significant
thus suggesting that rpS6 function might be differentially
affected in specific neuronal circuits by the absence of Mecp2.
Protein synthesis is severely affected in Mecp2
mutant brains
The phosphorylation of rpS6 is regulated by the ERK (31) and
mTOR pathways with the last being prominent in most cells,
and highly sensitive to mTOR inhibition (39). Moreover,
rpS6 phosphorylation correlates with the activation of the
protein synthesis apparatus (30).
With this in mind, we decided to analyze protein synthesis
in Mecp2 mutant mice at P56. Neuropathological signs are
already developed at this stage exemplified by motor unba-
lance, learning impairments as well as cognitive deficits and
anxious behavior (37) are already developed.
To have a read-out of protein synthesis, incorporation of
35S-methionine into new proteins was examined on in vitro
cultured brain slices of WT (n ¼ 3) and MeCP2 mutant
brains (n ¼ 3). This metabolic labeling showed a trend in
reduction in methionine incorporation (P ¼ 0.06) in the
mutants (Supplementary Material, Fig. S3), prompting us to
analyze the specific reduction in initiation of translation by
polysomal profiles.
Cytoplasmic cell extracts from Mecp2 mutant and WT brain
lysates were prepared and fractioned on a sucrose gradient.
Figure 3A shows cell extracts profiles in which the polysomal
fraction is evidently reduced in two different MeCP2
mutants (red line) when compared with WT (black line)
brains (WT, n ¼ 3; KO, n ¼ 3). Therefore, the overall pool
of active translating polyribosomes is abnormally diminished
in mutant brains where the disease has progressed. Indeed,
densitometric scanning of the P56 brain polysomal profiles
(Fig. 3B) showed a significant decrease in the area of
ribosomal peaks in the polysome fraction of Mecp2 null
mice with respect to WT littermates (decrease of 8+ 0.1%
of WT, n ¼ 3, P , 0.05). Consistently, there was an increase
in the area of ribosomal peaks in the mRNA-free part of the
gradient in Mecp2 null mice with respect to WT controls
(increase of 7.9+ 0.08% of WT, n ¼ 3, P , 0.05).
This dysfunction of initiation of the translation rate might
be caused by the general compromised state of the mutants
at this late phase of the disease. In alternative, this defect
might be an early event in the disease evolution that, nonethe-
less, remains detectable even at late stages of the pathology.
To discriminate between these two possibilities, we performed
polysomal profiles in young Mecp2 null animals at a pre-
symptomatic stage (P26). Noteworthy, cell extracts profiles
present a notable reduced polysomal fraction when comparing
Mecp2 null with WT brains (WT, n ¼ 3; KO, n ¼ 3) (Fig. 3C).
The densitometric scanning of the P26 brain polysomal pro-
files (Fig. 3D) showed a significant decrease in the area of
ribosomal peaks in the polysome fraction of Mecp2 null
mice with respect to WT littermates (decrease of 7.6+
0.04% of WT, n ¼ 3, P , 0.01). Consistently, there was an
increase in the area of ribosomal peaks in the mRNA-free
part of the gradient in Mecp2 null mice with respect to WT
controls (increase of 7.6+ 0.03% of WT, n ¼ 3, P , 0.01).
Human Molecular Genetics, 2011, Vol. 20, No. 6 1185
 at Universita degli Studi dell'Insubria on August 23, 2011
hm
g.oxfordjournals.org
Downloaded from
 
In line with this finding, the amount of Rack1, a major com-
ponent of translating ribosome, was mainly reduced in the
fast sedimenting fractions (7–10) where polyribosomes are
located in the MeCP2 null with respect to the control brain
lysates (Fig. 3D). Conversely, at this same stage initiation of
translation was found only minimally affected in the liver of
MeCP2 mutant with respect to WT animals (WT, n ¼ 3;
KO, n ¼ 3), a peripheral organ with an intense metabolic
activity (Fig. 3B). These data provide a first indication that
defects in the initiation of translational are an early sign of
the disease that accompanies or even precedes the initial
neurological impairment in the MeCP2 null mice.
A failure in initiation might have a general impact on global
mRNA translation or, alternatively, might affect specific tran-
scripts in particular. To address this issue, RNA was isolated
from each fraction of the ribosomal profiles of P26 Mecp2
mutant and WT brain lysates and transcript levels for a specific
gene were assessed by quantitative RT-PCR (qRT-PCR). We
selected two genes coding for molecules with a pivotal function
in neuronal activity and plasticity such as CAMKIIa and
PSD95. In addition, three genes not associated with a neuronal
function were also analyzed (Rack1, hnRNP A2/B1 and
GADPH). Finally, we assessed the levels of the 18S ribosomal
RNA (rRNA) which is incorporated in 40S ribosomal subunit.
In total agreement with polysomal profiles, in MeCP2 mutant
brains, the 18S rRNA was reduced in the polysome fraction
and enriched in the mRNA-free part of the gradient (Fig. 4A).
A similar trend was observed for CAMKIIa and PSD-95
mRNAs as well as for Rack1, hnRNP A2/B1 and GADPH
mRNAs (Fig. 4B–D). Indeed, polysomal incorporation of
these transcripts was significantly lower in Mecp2 null mice
with respect to WT (Fig. 4B–D). This observation can be quan-
titatively expressed by the percentage of messenger on poly-
somes (PMP), which is calculated by dividing the sum of the
Figure 2. S6 phosphorylation is reduced in the cortex, cerebellum and hippocampus of MeCP22/y animals. Representative western blots (top) and summary data
(bottom) showing p-rpS6 and total pS6 in whole-cell lysates from the cortex (A), cerebellum (B) and hippocampus (C) of P56 MeCP2 KO and WT mice.
Western blots were probed with antibodies to p-Ser235/236 S6, p-Ser240/244 S6 and total S6. Tubulin was included as a loading control. Blot quantitation
revealed that the phosphorylation of S6 at Ser235/236 is reduced in cortex, cerebellum and hippocampus of MeCP2 KO animals. rpS6 Ser240/244 phosphoryl-
ation was significantly reduced in MeCP2 KO cortex and cerebellum but not in the hippocampus. No difference was present in total rpS6 expression. Error bars
represent the standard error of the mean. ∗P , 0.05.
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quantitated signals of the last six fractions containing active
polysomes by the sum of the 11 fractions. In the case of
control tissues, the PMP value was over 60% for all six genes,
whereas it got reduced to "50% in Mecp2 mutant brains
(Fig. 4D). Taken together, these data demonstrate a comparable
reduction in the translation rate of all the tested mRNAs.
AKT/mTOR signaling is perturbed in Mecp2 mutant
brain tissue
mRNA translation is a highly regulated process and rep-
resents the final target of diverse signaling pathways that
sense both the stimuli from the external environment as
well as the metabolic needs. Therefore, we decided to inves-
tigate any changes in diverse intracellular pathways involved
in protein synthesis. It is well recognized that rpS6 is the
major substrate of p70 S6 kinase (S6K) which promotes
the phosphorylation of consecutive serine residues at the
rpS6 C-terminal part and thereby stimulating protein trans-
lation (30). Activation of the p70 S6K depends on multiple
phosphorylation events occurring in a hierarchical manner
within the C-terminal autoinhibitory domain (40). Interest-
ingly, the S6K phosphorylation levels were reduced in
brain lysates of P48 Mecp2 mutant with respect to WT
Figure 3. Initiation of translation is reduced in MeCP22/2 adult and young mice. (A) Polysomal profiles of P56 WT and MeCP2 KO mouse brain extracts.
Cytoplasmic brain extracts derived from P56 WT and MeCP2 KO mice were fractionated on a 15–50% (w/v) linear sucrose gradient. Polysomal profiles
show the difference in the initiation of translation between WT and MeCP2 null mice. Specifically, the increase in 80S and the decrease in polysomes peaks
indicate that the level of translation in MeCP2 KO is decreased. (B) Densitometric scanning quantification of P56 brain polysomal profiles is presented in a
bar graph. Error bars represent the standard deviations from the means. ∗P , 0.05. (C) Polysomal profiles of P26 WT and MeCP2 null mouse brain extracts.
Cytoplasmic brain extracts derived from P26 WT and MeCP2 KO mice were fractionated on a 15–50% (w/v) linear sucrose gradient. The same experiment was
carried out on mouse liver, showing little or no difference in translation between WT and MeCP2 KO. (D) Densitometric scanning quantification of the relative
area of ribosomal peaks of P26 brain polysomal profiles is presented in a bar graph. Error bars represent the standard deviations from the means. ∗∗P, 0.01.
(E) Fractions from polysomal profiles of P26 WT and MeCP2 null brains were collected, TCA concentrated and analyzed by SDS–PAGE. Proteins were probed
for MeCP2, Rack1 (marker of 40S, 80S and translating ribosomes) and eIF6 (marker of free 60S).
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littermates (decrease of 35+ 6% of WT; n ¼ 3 WT and KO;
P, 0.05) (Fig. 5A and B). In contrast, no appreciable
change was detected in S6K protein abundance between
Mecp2 null and WT brain lysates (Fig. 5A and B).
A large body of evidence has shown that the rpS6-S6K
pathway is tightly controlled by the mTOR kinase activity
which integrates signals from mitogenic growth factors, nutri-
ents, stress and cellular energy level to promote protein syn-
thesis (41,42). Therefore, we examined the abundance and
phosphorylation of mTOR at Ser2448, a biochemical indicator
of mTOR activation (41), in Mecp2 KO and WT brain lysates.
The phosphorylation of mTOR at Ser2448 was reduced in
whole-cell lysates of the brain ofMeCP2mutant mice (decrease
of 27+ 7%ofWT; n ¼ 3WTandKO;P , 0.05) relative to that
ofWT littermates (Fig. 5C andD). In contrast, the amount of the
total mTORprotein was equivalent in both genotypes indicating
a reproducible difference exclusively to its phosphorylated form
(Fig. 5C and D). rpS6 is known to be also activated by the
RAS-ERK signaling cascade through phosphorylation by the
p90 ribosomal S6K exclusively in Ser235/236 (31). Thus, we
examined the levels of the activation of Erk1/2 kinases in
brains lackingMecp2. No difference in ERK2 phosphorylation
was observed in the same mice (94.4+ 17% of WT levels, n ¼
11, P ¼ 0.56) (Fig. 6A and B).
The findings reported thus far suggest a rather specific
defect in mTOR signaling in the brain of MeCP2 KO mice.
At least two mTOR complexes exist, mTORc1, upstream of
rpS6, and mTORc2. The phosphorylation status of S473
depends directly by mTORc2 activity and therefore represents
an indication of the overall mTOR activity in the cell (43).
Interestingly, we found a consistent reduction in AKT
S473 phosphorylation in mutant Mecp2 compared with WT
P46 brain lysates (decrease to 45.7+ 9.5% of WT levels,
n ¼ 10, P ¼ 0.037) (Fig. 6C and D).
Figure 4. Polysomal incorporation of 18S rRNA as well as CAMKIIa, PSD95, Rack1, hnRNP A2/B1 and GADPH mRNAs is decreased in the absence of
MeCP2. Cytoplasmic brain extracts derived from P26 WT and MeCP2 null mice were fractionated on a 15–50% (w/v) linear sucrose gradient. Each gradient
was fractionated into 11 1-ml fractions, RNA was extracted from each fractions and qRT-PCR analyzes of total RNA in each fraction was carried out with
primers specific for 18S, CAMKIIa PSD95, Rack1, hnRNP A2/B1 and GADPH. Results pooled into five groups: Hydrosol (H), 40S, 60S, 80S and polysomes.
Error bars represent the standard deviations from the means (n ¼ 3). ∗P , 0.05 for KO versus WT by Student’s t-test. 18S, CAMKIIa and PSD95 mRNA levels
are significantly decreased in active polysomes from MeCP2 KO brain (A–D). These data suggest the decreased levels of mRNA translation in MeCP2 KO. (D)
Histogram of PMP is reported. PMP was calculated by comparing the mRNA level of the fractions containing active polysomes with the mRNA level from all 11
fractions.
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The difference in phospho-AKT appears to be attributable
to alterations in basal activation state, because total AKT
abundance did not differ significantly in mutant mice relative
to WT littermates (Fig. 6A and B).
In overall, these results provide evidence for a general dys-
function of the AKT/mTOR signaling associated with the
disease progression in Mecp2 mutant brains.
MeCP2 is not a ribosomal resident protein
To assess any direct involvement of MeCP2 in controlling
protein synthesis, we investigated its association with the ribo-
somal machinery. In polysomal profiles, MeCP2 was mainly
localized in fractions 1–5 partially co-fractionating with ribo-
somal subunits 40S, 60S and 80S as tested by immunoblotting
with two different antibodies on each fraction of the gradient
(see Materials and Methods). To determine whether the
co-sedimentation of MeCP2 with ribosomes is stable, we
repeated ribosomal profiles after treating cell extracts with
EDTA (30 mM) which causes complete dissociation of the
translating ribosomes into subunits and the release of polyribo-
somal mRNPs. In this case, ribosomal-associated proteins no
longer were collected from the fast-sedimenting gradient frac-
tions, but were retrieved from the fractions at the top of the
sucrose gradient (Supplementary Material, Fig. S4). In line
with this, Rack1, a protein stable associated with ribosomes,
after EDTA treatment was mostly located in the cellular
soluble content confirming the expected outcome. Neverthe-
less, under these conditions, the MeCP2 sedimentation
pattern was neither shifted into the lighter fractions nor
changed in other evident ways (Supplementary Material,
Fig. S4). These results indicate that MeCP2 is associated
with high-weighted molecular complexes but it is not stably
associated with ribosomal complexes.
Phosphorylation of rpS6 is abnormal in Mecp21/2
female mice
Mecp2y/2 mutants are the most utilized animal model to
evaluate harsh consequences of MeCP2 mutation. However,
the greatest number of the affected RTT patients is MECP2-
mutated heterozygote girls. Mecp2+/2 female mice possess
various phenotypic characteristics of RTT patients, such as
locomotor and autonomic alterations, abnormal cognitive
and emotional behavior as well as a relatively normal lifespan.
We thus analyzed if the phosphorylation of rpS6 is impaired
in the brain of 10 months old female heterozygous mutants
that showed clear signs of the pathology (i.e. tremors,
reduced size and severe locomotor defects). As shown in
Figure 7A, we found that the intensity of immunostaining
for the phosphorylated forms of rpS6 (Ser235/236 and
Ser240/244 sites) was drastically reduced in the brain of
Mecp2+/2 mutants compared with WT female animals of
the same age. The decrease in p-rpS6 levels was observed
throughout the layers of the S1 cortex and in the CA1 area
of the hippocampus (Fig. 7A). Indeed, OD analysis of the
immunolabeling intensity (Fig. 7B) showed a significant
decrease in rpS6 activation at both Ser235/236 (P , 0.001)
and Ser240/244 (P , 0.001) in the S1 cortex of MeCP2 het-
erozygous mutants. We found a 60.1% reduction in p-rpS6
(Ser235/236) activation in the cortex of Mecp2+/2 mice
with respect to WT littermates (n ¼ 5, P , 0.001), whereas
the activation of p-rpS6 (Ser240/244) was 41.9% less in
female mutants than in control animals (n ¼ 5, P , 0.001).
Similarly, there was a reduction in activated rpS6 immuno-
localization in the pyramidal cell layer of the CA1 area in
the hippocampus of female mutants compared with WT con-
trols (Fig. 8C; p-rpS6-Ser235/236: OD WT, 0.45+ 0.02 and
OD KO, 0.26+ 0.03, n ¼ 5, P , 0.001; p-rpS6-Ser240/244:
OD WT, 0.38+ 0.03 and OD KO, 0.21+ 0.03, n ¼ 5,
Figure 5. Suppression of mTOR signaling in MeCP22/y mouse brain. (A) Brain lysates from P26 WT and MeCP2 null mice were separated by SDS–PAGE, and
the phosphorylation of p70 S6K was analyzed by western blot. Western blots were probed with antibodies against p-Thr421/Ser424-p70 S6K and total p70 S6K.
GADPH was included as a loading control. Western blot analysis revealed that the phosphorylation of p70 S6K is basally reduced in MeCP2 KO brain.
(B) Densitometric scanning quantification of the relative abundance of p-p70 S6K is presented in a bar graph. The values correspond to the means of three
independent experiments. Error bars represent the standard deviations from the means. (C) The same experiment as in (A) was carried out with antibodies
to p-Ser2448-mTOR and total mTOR. Tubulin was included as a loading control. (D) Summary data showing the relative abundance of p-Ser2448-mTOR
in whole-brain lysates from MeCP2 KO and WT mice. The values correspond to the means of three independent experiments. Error bars represent the standard
deviations from the means. ∗P , 0.05.
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P, 0.01). No differences were found in total rpS6 expression
in the two areas examined between the Mecp2+/2 mutants
and the WT mice (Fig. 7A–C; P. 0.5). These results indicate
that altered levels of rpS6 activation can be found in an animal
model of RTT closely resembling the human pathology.
MeCP2 non-cell autonomous effect on rpS6
phosphorylation
Finally, we assumed that if Mecp2 loss impacts on such a
complex signaling pathway, its deficiency might lead to
non-cell autonomous effects. On the contrary, if deficits of
rpS6 activation were produced by a completely
cell-autonomous mechanism in heterozygous females only
cells expressing the null allele would exhibit a phenotype. To
test this hypothesis, we quantitatively analyzed p-rpS6 localiz-
ation in the S1 cortex of Mecp2 heterozygote females that
show the mosaic expression of null and wild-type Mecp2
alleles caused by the random inactivation of one X-linked
Mecp2 allele (44). Interestingly, the analysis of high magnifi-
cation confocal images showed that p-rpS6 immunofluores-
cence was evidently reduced not only in MeCP2-negative
neurons, but even in adjoining MeCP2 expressing cells
(Fig. 8A). Indeed, the measurement of the mean p-rpS6 fluor-
escence intensity in the cell soma (Fig. 8B) revealed no differ-
ences between MeCP2+ and MeCP22 neurons
(p-rpS6-Ser235/236, MeCP2+ versus MeCP22 cells, n ¼ 4,
P. 0.3; p-rpS6-Ser240/244, MeCP2+ versus MeCP22 cells,
n ¼ 4, P . 0.1). Note that in MeCP2+ cortical neurons of
Mecp2 heterozygote females, the immunofluorescence signal
for MeCP2 precisely co-localized with bright puncta of DAPI
counterstain in the nucleus (Fig. 8C). This finding indicates
that even a mosaic loss of MeCP2 in heterozygote female
tissuesmight exert a more general impairment in signaling path-
ways and its downstream effectors.
DISCUSSION
In this study, we identified how the phosphorylation of rpS6 is
broadly reduced across different brain areas and at different
stages in mice lacking Mecp2. Surprisingly, this defect is
detectable extremely early during post-natal development
soon before neurological signs of the disease are evidently
manifested. rpS6 abnormal low levels of phosphorylation are
noticeable in both Mecp2 null males and heterozygote
females and the dynamic of its reduction follows the worsen-
ing of the neurological conditions. Therefore, p-rpS6 might
represent a valuable biomarker of the disease onset and its
development. This is particularly significant for RTT that cur-
rently lacks any reliable molecular marker to follow its neuro-
pathological progression.
We observed that the phosphorylation of rpS6 is reduced in
both MeCP22 and MeCP2+ neurons in the brains of Mecp2
heterozygous female. This finding suggests that rpS6 phospho-
levels in MeCP2 expressing cells are deregulated by the pres-
ence of neighboringMecp2 null neurons. This might be caused
by the aberrant secretion from mutant neurons or glia cells of
soluble factor(s) with neurotoxic effects. It might be hypoth-
esized as well that the functional impairment of mutant
neurons inhibits neuronal activity in adjoining cells therefore
reducing rpS6 phosphorylation. Both possibilities are not
alternative and can be simultaneously occurring at a different
grade. Dysfunctions in non-cell autonomous pathways have
been already proposed to contribute to RTT progression. In
fact, Mecp2 mutant astrocytes as well as microglia were
found to induce multiple defects in WT neurons including
the dendritic patterning, synapse formation and microtubule
stability (45–48). However, our study indicated that p-rpS6
immunolabeling expression in glial cells is under the detection
level of high-resolution confocal microscopy, thus suggesting
that glia may not significantly contribute to the reduction in
rpS6 phosphorylation in the brain of MeCP2 KO mice. The
Figure 6. AKT phosphorylation is reduced in MeCP22/2 mouse brain. (A) Representative western blots (top) and summary data (bottom) showing pERK and
total ERK in lysates from whole brain of MeCP2 KO and WT mice. Tubulin was included as a loading control. (B) Blot quantification showed that no change in
pERK2 or total ERK2 was present in MeCP2 KO mice. Because of the extremely low levels of expression of ERK1, only ERK2 was analyzed. Error bars rep-
resent the standard error of the means. (C) Representative western blots showing pAKT and total AKT in whole-brain lysates from P56 MeCP2 KO and WT
mice. Note that the phosphorylation of AKT at Ser473 is decreased in MeCP2 KO animals. (D) Blot quantitation showed that pAKT is clearly reduced in MeCP2
KO mice. No effect was present on total AKT levels. Error bars represent the standard error of the means. ∗P , 0.05.
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elucidation of non-cell autonomous molecular mechanisms
acting in neuronal networks mosaic for the Mecp2 mutation
will be critical for our understanding of the disease pathogen-
esis in humans, which indeed affects primarily heterozygous
girls.
Herein, we discovered a reduction in AKT/mTOR signaling
associated with protein synthesis impairment in Mecp2 mutant
brains. To our knowledge, this is the first time that a cellular
molecular cascade with pleiotropic functions in controlling
cell homeostasis is found altered in RTT. These combined
molecular defects might be responsible at least in part for
the decreased number of excitatory hippocampal synapses
described in mice lacking Mecp2 (13,15,34–36). Neverthe-
less, RTT presents opposite molecular defects when compared
with similar neurodevelopmental disorders, such as Fragile X,
tuberous sclerosis and Pten-dependent autism, where, alterna-
tively, mTOR signaling and protein synthesis result aberrantly
up-regulated (49). Thus, RTT present peculiar molecular fea-
tures where the hypoactivation of the mTOR signaling and
limited protein synthesis is associated with reduced synaptic
connectivity as already hypothesized by Kelleher and Bear
(17). Despite the different molecular basis of RTT with
respect to the other mentioned diseases, the final output is
not so dissimilar, as in both cases, it causes a loss in neuronal
network performance. In this scenario, the overall clinical
neurological symptoms described as cognitive deficits,
autism and impaired language and communication might
arise from a positive as well as negative unbalance of the
same molecular processes.
A large body of evidence indicates that the AKT/mTOR sig-
naling pathway is a key modulator of the translation process,
and its deficiency is frequently associated with defects in
protein synthesis control (41,42,50). Consistent with this evi-
dence, we identified a notable reduction in the overall trans-
lation rate in Mecp2 mutant brains. This impairment was
evident by analyzing the polysomal fraction of ribosomal pro-
filing, whereas less significant in an ex vivo metabolic labeling
system. This may be due to the different sensitivity/noise
levels associated with the two different approaches. Alterna-
tively, a deficit in protein turnover in the mutant brains
might influence the final result of the metabolic labeling,
while not affecting in any means the ribosomal profiling
Figure 7. Activation of rpS6 is reduced in the brain of symptomatic MeCP2+/2 female mice. (A) Immunohistochemical detection of p-rpS6 (Ser235/236),
p-rpS6 (Ser240/244) and total rpS6 in the S1 cortex and in the CA1 area of the hippocampus in MeCP2+/2 female mice and in WT controls at 10 months
of age. Insets show higher magnification views of the immunolabeling pattern in layer V neurons of the S1 cortex. (B and C) Histograms show quantitative
analysis of the labeling intensity of p-rpS6 and total rpS6 expression in layers I–VI of the S1 cortex as well as in the CA1 pyramidal cell layer of the hippo-
campus. The expression of p-rpS6 (Ser235/236) and p-rpS6 (Ser240/244) is significantly decreased in MeCP2+/2 mice compared with WT controls in each
cortical layer (B) as well as in the CA1 area of the hippocampus (C) compared with control animals. Total rpS6 immunostaining intensity is unchanged
between genotypes in the two areas examined. Data are expressed as the mean+SEM. ∗∗P , 0.01, ∗∗∗P , 0.001 (scale bars, 50 mm).
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which represents a snapshot of the initiation of translation.
Future studies will investigate whether protein turnover is
impaired in MeCP2 mutant brains.
Intriguingly, protein synthesis defects are occurring very
early in RTT. Even if, at present, we cannot indicate whether
this translational defect stands as a cause or an early effect of
the disease, it is likely that it contributes to the overall
progression of the disease. In this study, we did not address
whether the rate of local protein synthesis is similarly affected.
However, the reduction in mTOR activity is such pervasive in
Mecp2 mutant brains that is likely to impact on both global
and local synthesis processes in comparable extent.
To determine whether translational repression in Mecp2
mutants is affecting different transcripts with a similar
Figure 8. Alterations of rpS6 phosphorylation are non-cell autonomous in symptomatic MeCP2+/2 female mutants. (A) Representative laser confocal images
show double-immunofluorescence labeling for p-rpS6 (Ser235/236) or p-rpS6 (Ser240/244) (green) and MeCP2 (red) in layer V neurons of the S1 cortex of WT
and MeCP2+/2 mice. Neurons lacking MeCP2 immunoreactivity in female MeCP2+/2 mice are indicated (arrowheads). Note that immunofluorescence signal
for p-rpS6 (Ser235/236) and p-rpS6 (Ser240/244) is noticeable reduced in neurons of MeCP2+/2 mice compared with WT. No obvious differences in staining
intensity are detectable between MeCP2+ and MeCP22 neurons in MeCP2+/2 cortical sections. (B) Histograms show quantitatively that, compared with WT
controls, there is a significant reduction in p-rpS6 (Ser235/236) and p-rpS6 (Ser240/244) immunofluorescence in MeCP2+/2 mice that occurs with no statistically
significant differences both in MeCP2+ and MeCP22 cortical neurons. (C) Fluorescence image showing MeCP2 immunoreactivity in combination with DAPI
counterstain in the S1 cortex of female MeCP2+/2 mice. Data are expressed as the mean+SEM. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001 (scale bar, 20 mm).
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magnitude, we evaluated the effective amount of mRNAs on
polysomes for non-directly related genes with a pivotal role
in neuronal activity like CAMKIIa and PSD-95. Interestingly,
we found that the polysomal incorporation of the two tran-
scripts was significantly lower in Mecp2 null mice with
respect to WT. A similar trend was observed for Rack1,
hnRNP A2/B1 and GADPH mRNAs. These three genes
code for molecules that are not involved in neuronal activity
and plasticity. Although restricted to the analysis of some
genes, these results indicate that the translation impairment
is not an event restricted to only few gene transcripts that
impact to their protein production rate in similar levels.
On this basis, we favor the idea that a widespread limited
protein production in Mecp2 null neurons might restrain
over time their metabolic activity and, ultimately, their excit-
ability and plasticity.
Given that MeCP2 is a chromatin-associated transcriptional
regulator, a large effort has been put in identifying the altered
gene expression occurring in Mecp2 mutant brains. However,
a relative small amount of genes have been identified to be
aberrantly expressed that do not account for fully explaining
the development of the neuropathological signs (1,27,28).
Why this is the case it remains still elusive. It has been pro-
posed that the disease might be rooted in a genome-wide,
but subtle, deregulation of global gene expression levels
(51). Alternatively, the pathological gene alterations are
strictly neuronal cell type specific and arduous to be identified
in the expression profile studies conducted so far on entire
brain subregions (52). Nevertheless, we described a new
level of complexity of the disease represented by the wide-
spread dysregulation of the protein synthesis process.
Considering our results, gene functional impairment in RTT
might result from the sum of deregulated gene expression fol-
lowed by a limited capability to produce the functional proteins.
Given the alterations that we discovered in two closely
related processes like AKT/mTOR signaling and the protein
synthesis rate, we suggest that a defect in this cellular
pathway is responsible for the altered translational control in
Mecp2 mutant neurons. In contrast, we have not found any
evidence for a direct role of MeCP2 in the ribosomal machin-
ery controlling translational processes. This is also consistent
with the subcellular localization of MeCP2 almost exclusively
confined in the nucleus of differentiated neurons (11,44,53).
Further, MeCP2 is excluded from nucleoli in the nuclear com-
partment where ribosomal genesis is mainly taking place
(54,55) (S. Ricciardi and V. Broccoli, unpublished results).
However, we cannot exclude that MeCP2 might regulate
translation initiation by associating with components of the
pre-initiation complex (56). This might be also consistent
with the ability of MeCP2 to bind RNA and regulate its pro-
cessing (57). This possibility warrants future investigations
to be better delineated.
In conclusion, we identified the AKT/mTOR signaling as a
molecular pathway down-regulated in Mecp2 null neurons.
Consistent with this finding, rpS6 phosphorylation is reduced
in large areas of the Mecp2 male null or female heterozygous
brains providing an interesting biomarker for following the
dynamics of the pathology. Finally, the general process of
protein synthesis was found evidently impaired surprisingly
even at early pre-symptomatic stage, making likely its
contribution to the progression of the disease. Although our
results revealed the translational control as an additional
process altered by the pathological process; nevertheless,
they provide a novel context where therapeutic interventions
can be developed to successfully restrain or ameliorate the
development of RTT.
MATERIALS AND METHODS
Animals
The experiments performed in this study were conducted in
accordance with European Community Council Directive 86/
609/EEC for care and use of experimental animals with proto-
cols approved by the Italian Minister for Scientific Research.
To obtain the litters of WT animals and Mecp2 mutants
used for this study, heterozygous Mecp2tml.lJae mice with
exon 3 deletion in Mecp2 (8) were crossed to C57BL6 for
one generation, followed by breeding among offspring and
were maintained on a mixed background. Age-matched litter-
mates were used in all experimental conditions to avoid poss-
ible consequences of genetic background unrelated to the
Mecp2 mutation (37).
Immunohistochemistry and immunofluorescence
Animals were anesthetized with an intraperitoneal injection of
chloral hydrate and transcardially perfused with ice cold 4%
paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.4).
After perfusion, the brains were dissected and kept in the
same fixative solution overnight at 48C. After several
washes in 0.1 M PB, the brains were then cryoprotected by
immersion in 10, 20 and 30% sucrose solutions and sub-
sequently cut in 30-mm sections with a cryostat. Cryosections
were collected in phosphate-buffered saline (PBS, 0.01 M, pH
7.4) and processed for free-floating immunohistochemistry as
described (58). After a blocking step in a PBS solution con-
taining 0.05% Triton X-100 and 10% normal goat serum
(NGS), sections were then incubated overnight at room temp-
erature with the following primary antibodies: rabbit anti-
phospho-rpS6 (Ser235/236) (1:100); rabbit anti-phospho-rpS6
(Ser240/244) (1:200); rabbit anti-rpS6 (1:100) from Cell Sig-
naling Technology (Danvers, MA, USA). Antibodies were
diluted in PBS with 3% NGS and 0.05 Triton X-100. Sections
were then washed in PBS (4 × 10 min), incubated for 1 h with
goat anti-rabbit biotinylated secondary antibodies (1:250;
Vector Labs, Burlingame, CA, USA) diluted in 3% NGS
and 0.05% Triton X-100 in PBS and transferred to a solution
containing a biotin–avidin complex (1:100,Vector Labs). The
peroxidase reaction product was visualized by incubation in a
solution containing 3,3′-diaminobenzidine (0.05% in Tris–
HCI, pH 7.6) with 0.01% H2O2 for 3 min. Sections were
mounted on gelatin-coated glass slides and observed with a
light microscope (Eclipse 800, Nikon, Japan) equipped with
a CCD camera (Axiocam HRc, Zeiss, Germany).
Double immunofluorescence was performed with simul-
taneous addition of the primary antibodies as described (59).
Briefly, cryosections were blocked in 10% normal donkey
serum with 0.05% Triton X-100 in PBS for 1 h, then incubated
at room temperature overnight with the following primary
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antibodies: rabbit anti-phospho-rpS6 (Ser235/236) (1:100),
rabbit anti-phospho-rpS6 (Ser240/244) (1:200), goat anti-
MeCP2 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), mouse anti-NeuN (1:100, Chemicon, Billerica, MA,
USA) and mouse anti-GFAP (1:100, Cell Signaling Technol-
ogy). After PBS washing, sections were incubated with sec-
ondary fluorescent antibodies (donkey anti-rabbit Alexa 488,
Molecular Probes; donkey anti-goat Alexa 594, Invitrogen;
donkey anti-mouse Alexa 594, Molecular Probes) for 1 h
and, after several PBS rinses, incubated with DAPI (1:500,
Invitrogen), mounted on gelatin-coated glass slides and
observed with a confocal microscope (Zeiss LSM-5 Pascal,
Germany).
Immunohistochemical data analysis
Total labeling of peroxidase in immunohistochemistry exper-
iments was analyzed quantitatively by measuring OD on
micrographs (10×) using a public-domain dedicated software
(ImageJ, USA) by an operator blinded to the genotype.
Measurements of OD in the cortex were obtained from
100 × 50 mm measuring boxes that were randomly placed in
each cortical layer. OD values in the hippocampus were
obtained from the CA1 pyramidal cell layer. Histograms illus-
trate the average OD obtained from three repeated measures in
4–5 sections per experimental animal at all ages examined
(male WT n ¼ 3; male MeCP2 KO n ¼ 3; female WT n ¼
5; female MeCP2+/2 n ¼ 5). The mean OD of the corpus cal-
losum was subtracted as background staining.
Double-fluorescence micrograph of the S1 cortex samples
was acquired with a laser scanning confocal microscope,
using the multitrack mode to avoid fluorescence crosstalk
(pinhole: 1.0 airy unit). For the quantitative analysis of
phospho-rpS6 fluorescence labeling in cortical neurons,
Z-series stacks of four consecutive confocal sections (512 ×
512 pixels) spaced by 2 mm were acquired at 20×. Images
from both channels were overlaid and background labeling
was subtracted. Fluorescence levels were analyzed on confocal
images by measuring mean pixel intensity in either MeCP2-
positive or MeCP2-negative neurons using ImageJ software.
Histograms represent the mean fluorescence intensity calcu-
lated in at least 50 cortical neurons per animal (female WT
n ¼ 4; female MeCP2+/2 n ¼ 4). All data are presented as
the mean+SEM. Statistical analysis was done by Student’s
t-test as well as one- or two-way ANOVA using GraphPad
Prism software (La Jolla, CA, USA). For presentation,
digital micrographs were processed with the software
ImageJ. Files were imported into Adobe Photoshop (Adobe
Systems, San Jose, CA, USA), where images were cropped.
Polysomal profiles
Polysomal profiles were performed as described previously
(60), with some modifications. Brain tissues were extracted
from the skull and homogenized in 50 mM Tris–HCl (pH
7.4), 100 mM NaCl, 30 mM MgCl2, 0.1% NP40, 100 mg/ml
of cycloheximide, 40 U/ml of RNasinw and protease inhibitor
cocktail (Sigma-Aldrich). Whole-brain extracts were clarified
at 48C for 10 min at 15 000g. The equivalent of 10 absorbance
units at 254 nm were layered on a 15–50% sucrose gradient in
50 mM Tris–acetate, pH 7.5, 50 mM NH4Cl, 12 mM MgCl2 and
1 mM DTT and centrifuged at 48C in a SW41Ti Beckman rotor
for 3.5 h at 39 000 rpm. The absorbance at 254 nm was
recorded by BioLogic LP software (Bio-Rad) and fractions
were collected. In order to disrupt 80S ribosomes and poly-
somes, total extracts were treated with 30 mM EDTA for
10 min at 48C. EDTA-treated and -untreated samples were
then loaded on a sucrose gradient. Fractions were precipitated
with 10% TCA (trichloroacetic acid) according to the standard
protocol, separated on SDS–PAGE and analyzed by western
blot. RNA was isolated from each fraction by phenol:chloro-
form:isoamilalcool (25:24:1) (Sigma-Aldrich) and mRNAs
were analyzed by qRT-PCR. For quantitative measurements,
polysomal profiles were scanned and the area of ribosomal
peaks assessed with ImageJ (NIH) software.
Metabolic labeling
Six 400-mm sections were prepared from whole brain per
animal (average age P40) using a tissue slicer. The slices
were maintained in carbogenated, at 32.58C ACSF (120 mM
NaCl, 2.5 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2, 26.2 mM
NaHCO3, 1 mM NaH2PO4, 11 mM Glucose) for 1.5 h. Follow-
ing a 1.5 h recovery, slices were transferred to 15 mm diam-
eter netwells (Corning) containing 5 ml of carbogenated
ACSF. For each animal, three slices were incubated for
30 min in carbogenated ACSF with 100 mg/ml of cyclohexi-
mide. Slices were then incubated in carbogenated ACSF
containing 11 mCi/ml of Promix 35S-labeled methionine
(Amersham) for 1 h. Netwells were then transferred to
12-well dish containing ice-cold dissection buffer to stop
protein synthesis and remove the excess of 35S-labeled meth-
ionine. Slices were subsequently removed and homogenized
in ice-cold lysis buffer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 1% NP40 and a mix of proteases inhibitors from
Sigma-Aldrich). Extracts of 10 ml were TCA-precipitated on
glass microfibre filters (Whatman) and counted. Obtained
values were normalized by sample protein content, quantified
using the bicinchoninic acid protein assay (Pierce). Final data
were expressed as the ratio between the incorporated counts
per minute (CPM) of non-treated slices and the CPM of
cycloheximide-treated slices.
Western blotting
Brain tissues were extracted from the skull and homogenized
in lysis buffer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1%
NP40, 0.1% SDS and a mix of phosphatases and proteases
inhibitors from Sigma-Aldrich) at 48C. Lysates were clarified
by centrifugation for 15 min at 18 000g, and protein concen-
tration of the supernatant was determined using bovine
serum albumin (BSA) as a standard (Bradford reagent assay,
Sigma-Aldrich). Total lysates were boiled in SDS sample
buffer, separated by SDS–PAGE and blotted to nitrocellulose
membrane (Amersham). Filters were blocked in tris-buffered
saline Tween-20 (0.1%) (TBST) (10 mM Tris–HCl, pH 8.0,
150 mM NaCl and 0.05% Tween-20) plus 5% BSA
(Sigma-Aldrich) and incubated with primary antibodies
for 16 h at 48C. The following primary antibodies were
used: rabbit polyclonal anti-MeCP2 (1:1000, Sigma-Aldrich),
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rabbit polyclonal MeCP2 (1:1000, Lansberger’s group), rabbit
polyclonal anti-phospho-p70 S6K (Thr421/Ser424) (1:1000,
Cell Signaling Technology), rabbit polyclonal anti-p70 S6K
(1:1000, Cell Signaling Technology), rabbit polyclonal
anti-phospho-mTOR (Ser2448) (1:1000, Cell Signaling Tech-
nology), rabbit monoclonal mTOR (1:1000, Cell Signaling
Technology), rabbit polyclonal anti-phospo-AKT (Ser473)
(1:1000, Cell Signaling Technology), mouse monoclonal anti-
diphosphorylated ERK-1&2 (pERK) (1:1000, Sigma-Aldrich),
mouse monoclonal anti-non-phosphorylated ERK-1&2
(1:1000, Sigma-Aldrich), mouse monoclonal anti-GADPH
(1:5000, Millipore). After washing three times with TBST,
filters were incubated with peroxidase-conjugated secondary
antibodies (anti-mouse or rabbit IgG; 1:5000) (Amersham)
for 1 h at room temperature. Detection was performed by
enhanced chemiluminescence (EuroClone, Pero, Italy). For
quantitative measurements, autoradiographs were scanned
and signal intensity assessed with ImageJ (NIH) software.
Quantitative RT-PCR
An equal volume of RNA from each eleven-numbered fraction
was reverse transcribed with random hexamer primers by
Transcriptor High Fidelity cDNA Synthesis Kit (Roche),
according to the manufacturer’s instructions. Real-time PCR
was performed with specific primers and SsoFastTM
EvaGreenw Supermix (Bio-Rad) in a C1000TM Thermal
Cycler (Bio-Rad). The amount of template and the number
of amplification cycles were preliminarily optimized for
each PCR to avoid conditions of saturation. For mRNA quanti-
fication, we constructed a standard curve with a serial dilution
of RNA. For the experimental sample, the mRNA level was
calculated using its standard curve obtained for that mRNA.
The primer pairs used for the qRT-PCR were as follows:
5′-GTAACCCGTTGAACCCCATT-3′ (forward) and 5′-CC
ATCCAATCGGTAGTAGCG-3′ (reverse) for 18S mRNA;
5′-GGACACCTGGATACCTCTCCC-3′ (forward) and 5′-GT
ACAGGCGATGCTGGTCTT-3′ (reverse) for CAMKIIa
mRNA; 5′-GTGGGCGGCGAGGATGGTGAA-3′ (forward)
and 5′-CCGCCGTTTGCTGGGAATGAA-3′ (reverse) for
PSD95 mRNA; 5′-AGGGCCACAATGGATGGGTA-3′
(forward) and 5′-TCTGGTCAGCTTCCACATGAT-3′
(reverse) for Rack1 mRNA; 5′-GGCTATAATGGGTATGG
AGGAG-3′ (forward) and 5′-GGCATGGACTGTGGTCAT
GA-3′ (reverse) for hnRNP A2/B1 mRNA; 5′-GGCAT
GGACTGTGGTCATGA-3′ (forward) and 5′-TTCACCACC
ATGGAGAAGC-3′ (reverse) for GADPH mRNA.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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